Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $139.18M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 4.34M
Average 8.14M
HUMA Total Current Liabilities
All obligations due within one year.
Humacyte, Inc.NASDAQ: HUMA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 19.2% from a year ago
Total current liabilities stood at $16.19M at the end of Q1 FY2026, down 19.2% from a year earlier and down 11.9% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.
Context
- Total current liabilities amounted to 14.6% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -19.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.37M USD
- Year-over-year change
- -7.9%
- 4-year CAGR
- +13.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.37M | -7.9% |
| FY2024 | 2024-12-31 | 19.95M | +8.2% |
| FY2023 | 2023-12-31 | 18.44M | -5.8% |
| FY2022 | 2022-12-31 | 19.58M | +77.2% |
| FY2021 | 2021-12-31 | 11.05M | — |
Total Current Liabilities vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's Mar 2026 total current liabilities of $16.19M is the 8th highest of the 11 companies compared; the peer median is $26.28M.
- Its year-over-year change of -19.2% is the 8th highest of 11, against a peer median of +3.2%.
- Total current liabilities amounts to 14.6% of total assets for HUMA, versus a peer median of 10.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.97B | +97278.1% | +7.7% | 2.3% | |
| Mar 2026 | $135.58M | +30.5% | +16.7% | 31.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $34.37M | -30.4% | -34.1% | 14.0% | |
| Mar 2026 | $33.37M | +53.4% | +29.1% | 12.5% | |
| Mar 2026 | $19.2M | +4.1% | +3.6% | 5.7% | |
| Mar 2026 | $17.45M | -56.6% | -28.5% | 8.0% | |
| Mar 2026 | $16.19M | -19.2% | -2.1% | 14.6% | |
| Mar 2026 | $11.83M | +66.0% | -25.1% | 35.7% | |
| Mar 2026 | $8.34M | +2.3% | +5.4% | 4.7% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -1.1% | 4.9% |
| Peer median (excluding HUMA) | $26.28M | +3.2% | +3.1% | 10.2% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 217.5M | 149.77M | 80.45M | 44.94M | 50.5M |
| Short-term Investments | 8M | 2.11M | 0 | 0 | 0 |
| Net Receivables | 176K | 31K | 0 | 0 | 441K |
| Inventory | 0 | 0 | 0 | 0 | 13.59M |
| Other Current Assets | 0 | 2.3M | 2.83M | 2.92M | 3.27M |
| Total Current Assets | 229.34M | 154.21M | 83.28M | 47.86M | 67.8M |
| Property, Plant & Equipment (Net) | 57.19M | 50.09M | 44.1M | 38.55M | 47.69M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 209K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 841K | 51.46M | 672K |
| Total Non-current Assets | 57.19M | 50.09M | 44.95M | 90.01M | 48.57M |
| Total Assets | 286.53M | 204.3M | 128.22M | 137.87M | 116.37M |
| Account Payables | 2.09M | 1.6M | 6.49M | 4.49M | 5.4M |
| Short-term Debt | 0 | 8.57M | 0 | 0 | 0 |
| Tax Payables | 173K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.12M | 4.23M | 5.29M | 7.37M | 6.63M |
| Total Current Liabilities | 11.05M | 19.58M | 18.44M | 19.95M | 18.37M |
| Long-term Debt | 27.36M | 20.34M | 38.6M | 63.35M | 35.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 104.16M | 28.61M | 41.34M | 156.97M | 32.47M |
| Total Non-current Liabilities | 153.31M | 67.79M | 96.23M | 170.59M | 94.89M |
| Total Liabilities | 164.36M | 87.37M | 114.68M | 190.54M | 113.26M |
| Common Stock | 10K | 10K | 10K | 13K | 20K |
| Retained Earnings | (414.57M) | (426.54M) | (537.31M) | (686.02M) | (726.85M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 122.17M | 116.93M | 13.55M | (52.67M) | 3.11M |
| Total Debt | 51.18M | 50.07M | 57.45M | 16.54M | 64.85M |
| Net Debt | (166.32M) | (99.71M) | (23M) | (28.4M) | 14.35M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.